Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs6.71 M21.23 M32.55 M33.3 M26.09 M16.68 M18.32 MRecherche et développement13.29 M42.79 M61.46 M93.79 M70.68 M17.5 M24.46 MRésultat d'exploitation-20 M-64.02 M-104.02 M-125.47 M-100.9 M-102.27 M-109.94 MTotal des produits hors exploitation-1.28 M334 K3.22 M7.64 M3.96 M1.24 M1.43 MCharges d'intérêts, nettes des intérêts capitalisés367 K3 000—————Résultat hors exploitation, hors charges d'intérêts-367 K-3 00000000Revenus/dépenses exceptionnels-1.28 M334 K3.22 M7.64 M3.96 M1.24 M1.43 MRésultat avant impôts-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-135.81 MPart des actionnaires dans le résultat———————Impôts-4.3 M-13.5 M-20.4 M-28.3 M-20.7 M0—Intérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts———————Résultat net avant activités abandonnées-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-129.41 MActivités abandonnées———————Résultat net-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-129.41 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-129.41 MBénéfice par action de base (BPA de base)——-25.3-30.9-25.2-24.7-24.09Bénéfice par action dilué (BPA dilué)——-25.3-30.9-25.2-24.7-24.09Nombre moyen d'actions de base en circulation——3.77 M3.8 M3.85 M4.28 M—Nombre d'actions en circulation après dilution——3.77 M3.8 M3.85 M4.28 M—EBITDA-19.54 M———-100.44 M——EBIT-19.8 M———-100.91 M——Coût des ventes———————Autres coûts des ventes———————Amortissements (flux de trésorerie)253 K972 K423 K-445 K455 K643 K436 K
LeonaBio, Inc. - Common Stock
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.